Table 1.

The clinical baseline data and univariate survival analysis of 191 patients.

Factor	Cases (%)	Median OS (month)	HR (95% CI)	P value
Sex
Male	153 (80.1)	41.8		0.563
Female	38 (19.9)	35.7	1.13 (0.75–1.72)
Age
≤49	102 (53.4)	41.2		0.853
>49	89 (46.6)	41.1	1.03 (0.74–1.45)
Pathological type
WHO type I/II	14 (7.3)	41.4		0.198
WHO type III	177 (92.7)	19.2	1.46 (0.82–2.59)
KPS
<80	50 (26.2)	15.9		<0.001
≥80	141 (73.8)	48.8	0.35 (0.24–0.51)
T stage
1-2	38 (19.9)	51.9		0.440
3-4	153 (80.1)	34.0	1.19 (0.77–1.84)
N stage
0-1	27 (14.1)	64.7		0.007
2-3	164 (85.9)	36.4	2.07 (1.21–3.57)
Number of metastatic organs
Single	126 (66.0)	51.2		<0.001
Multiple	65 (34.0)	18.9	2.41 (1.69–3.45)
Number of metastases
1–3	61 (31.9)	68.5
4-5	33 (17.3)	53.7	1.40 (0.80–2.43)	0.244
>5	97 (50.8)	17.9	4.37 (2.79–6.86)	<0.001
Bone metastasis
Yes	124 (64.9)	43.2		0.747
No	67 (35.1)	28.5	0.94 (0.66–1.35)
Lung metastasis
Yes	52 (27.2)	23.7		0.026
No	139 (72.8)	45.7	0.66 (0.45–0.95)
Liver metastasis
Yes	70 (36.6)	20.7		<0.001
No	121 (63.4)	50.4	0.49 (0.35–0.70)
Nasopharyngeal radiotherapy
Yes	149 (78.0)	47.4		<0.001
No	42 (22.0)	16.1	2.80 (1.89–4.14)
Dose at primary tumor
<70 Gy	25 (16.8)	18.4		<0.001
≥70 Gy	124 (83.2)	51.1	0.38 (0.23–0.63)
Platinum-containing chemotherapy
Doublet	128 (69.6)	39.4		0.162
Triplet	56 (30.4)	39.6	0.76 (0.51–1.12)
Cycles of first-line chemotherapy
<6	124 (64.9)	37.3		0.045
≥6	67 (35.1)	48.2	0.69 (0.48–0.99)
Metastasis treatment
Yes	44 (23.0)	29.9		0.552
No	147 (77.0)	43.7	0.89 (0.61–1.31)